TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07850063: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-

Sponsor: Boehringer Ingelheim · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$11,550,280

Rescue Site Savings

+$7,637,328

Unlock Full NCT07850063 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07850063 Rescue Dossier →